US-based biopharmaceutical services company Quintiles is expanding its remit in Russia by launching its first commercial project in the market. The project involves a 40-strong sales team and comes after Quintiles set up a local legal entity to deliver commercial operations in the country and appointed Sergey Smirnov as head of business development & operations,
Quintiles is considering setting up at least two more Prime Sites in the UK to make the most of what it regards as a still fertile environment for clinical trials. The US-based biopharmaceutical services company established the first of its international network of Prime Sites at Queen Mary, University of London in 2007. The company recently gave a further vote of confidence to the UK as a key location for clinical research by investing in a clinical research facility – part of the new William Harvey Heart Centre – at the same site.